Creation of an Expert Curated Variant List for Clinical Genomic Test Development and Validation: A ClinGen and GeT-RM Collaborative Project

Short Running Title (40 characters): Creation of a Curated Variant List

Emma Wilcox^{1*}, Steven M. Harrison^{1*}, Edward Lockhart², Karl Voelkerding³, Ira M. Lubin⁴, ClinGen Expert Panels⁵ Heidi L. Rehm^{1,6^}, Lisa Kalman^{7^}, Birgit Funke^{8^}

*, ^ these authors contributed equally

¹Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA
(ewilcox@broadinstitute.org, sharriso@broadinstitute.org, hrehm@broadinstitute.org)

²Informatics and Data Science Branch, Division of Laboratory Systems, Centers for Disease Control and Prevention, Atlanta, GA coy3@cdc.gov

³Voelkerding Consulting, Salt Lake City, UT

⁴Quality and Safety Systems Branch, Division of Laboratory Systems, Centers for Disease Control and Prevention, Atlanta, GA iblo@cdc.gov

⁵See Supplemental Table 1

⁶Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA

⁷Informatics and Data Science Branch, Division of Laboratory Systems, Centers for Disease Control and Prevention, Atlanta, GA LJK0@cdc.gov

⁸Division of Genomic Health, Sema4, Stamford, CT

Corresponding Author:

Lisa Kalman, PhD
Informatics and Data Science Branch
Division of Laboratory Systems
Office of Surveillance, Epidemiology, and Laboratory Services
Centers for Disease Control and Prevention
1600 Clifton Road
Mailstop V24-3
Atlanta, GA 30333
(404) 498-2231
LKalman@cdc.gov

Disclosures:

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry or the National Institutes of Health. Use of trade names and commercial sources is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention, the Public Health Service, the US Department of Health and Human Services or the National Institutes of Health.

Acknowledgements:

ClinGen is primarily funded by the National Human Genome Research Institute (NHGRI), through the following three grants: U41HG006834, U41HG009649, U41HG009650. ClinGen also receives support for content curation from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), through the following three grants: U24HD093483, U24HD093486, U24HD093487.

Abstract (220 words max)

Modern genomic sequencing tests often interrogate large numbers of genes. Identification of appropriate reference materials for development, validation studies, and quality assurance of these tests poses a significant challenge for laboratories. It is difficult to develop and maintain expert knowledge to identify all variants that must be validated to assure analytic and clinical validity. Additionally, it is usually not possible to procure appropriate and characterized genomic DNA reference materials containing the number and scope of variants required. To address these challenges, the Centers for Disease Control and Prevention's Genetic Testing Reference Material Program (GeT-RM) has partnered with the Clinical Genome Resource (ClinGen) to develop a publicly available list of expert curated, clinically important variants. ClinGen Variant Curation Expert Panels nominated 546 variants found in 84 disease associated genes, including common pathogenic and difficult to detect variants. Variant types nominated included 346 SNVs, 104 deletions, 37 CNVs, 25 duplications, 18 deletion-insertions, 5 inversions, 4 insertions, 2 complex rearrangements, 3 in difficult to sequence regions, and 2 fusions. This expert-curated variant list is a resource that provides a foundation for designing comprehensive validation studies and for creating *in silico* reference materials for clinical genomic test development and validation.

Introduction

Genetic testing has evolved from interrogating small sets of known, pathogenic variants in one or a few genes using targeted genotyping assays or Sanger sequencing to examining hundreds or thousands of genes at a time using next generation sequencing (NGS). Large gene panels are now the norm in many clinical areas, such as hereditary cancer and cardiomyopathy, and are particularly useful for disorders with locus and allelic

heterogeneity. Offerings from molecular testing laboratories range from single disorder to multi-disorder panels, the latter often allowing molecular refinement of the initial clinical diagnosis (National Institutes of Health, Genetic Testing Registry <https://www.ncbi.nlm.nih.gov/gtr/> accessed 5/6/2021).

While NGS has advanced many aspects of genetic testing, this technology has made the task of designing and developing analytically and clinically valid tests more complex. This process requires deep clinical and genetic expertise to understand the clinically relevant variant spectrum, and characterization of genomic context as high GC content, highly homologous genes, or repetitive sequences pose challenges for most current NGS technologies.^{1, 2} When examining only one or a few well-studied genes, sufficient expertise to identify clinically important variants can be developed easily, but this aspect of test design and development does not scale to assays that examine hundreds or thousands of genes.³ Laboratories often cannot procure reference materials (RMs) that encompass the scope of variants and variant types needed for NGS test development and validation because the supply of available characterized genomic DNA samples from cell lines or patient samples is limited and does not cover the range of genes and variants often included in NGS assays. Finally, traditional patient derived RMs, such as genomic DNA from cell lines, typically contain only 1 or 2 clinically important variants per sample, which can significantly increase the number of samples needed, and thus the complexity and cost of a validation study when large numbers of variants need to be addressed.

Proper analytical validation of genomic tests and large test panels requires a combination of approaches: To ensure optimal confidence in the ability of a given technology to detect variants within a genome or subregion (e.g., exon), large numbers of variants for each clinically relevant type (SNVs, insertions, deletions, SVs) need to be analyzed. In addition, test developers should demonstrate the test's ability to detect specific clinically important variants particularly when they are technically challenging (Food and Drug Administration <https://www.fda.gov/media/99208/download>, accessed 3/23/2021; College of American Pathologists,

Molecular Pathology 2020 checklist <https://www.cap.org/> registration required, accessed 3/23/2021).⁴

Different types of reference materials have been created to meet these needs.

The 1000 Genomes project HapMap samples (1000 Genomes Project

<https://www.internationalgenome.org/home>; accessed 10/11/2020) were the first generation of characterized

genomes that were publicly available. More recently, the National Institute for Standards and Technology (NIST)

Genome in a Bottle project has characterized 7 publicly available genomes including NA12878 and two

son/mother/father trios of Ashkenazi Jewish and Han Chinese ancestry for use as reference materials (NIST

<https://www.nist.gov/programs-projects/genome-bottle> accessed 5/10/2021).^{5, 6} These samples have been

extensively characterized using a number of different technologies and variant calling methods covering over

90% of the genome. NIST has generated publicly available, high confidence benchmarking data sets that have

been widely used by the clinical testing community and are now also covering structural variants, and variants in

highly homologous regions.⁷ In addition, Illumina produced a set of over 4.7 million phased variants from 17

samples of a large multigenerational pedigree.⁸ These data sets are excellent resources for establishing general

analytical performance across various variant types, but do not meet the additional need to validate specific

clinically important variants. Other publicly available genomic DNA samples, such as those characterized by the

Center for Disease Control and Prevention's Genetic Testing Reference Material Program (GeT-RM

<https://www.cdc.gov/labquality/get-rm/index.html> accessed 10/11/2020) and samples available from

repositories such as Coriell Institute for Medical Research (Coriell <https://www.coriell.org/> accessed 5/10/2021)

or the American Type Culture Collection (ATCC) (ATCC <https://www.atcc.org/> accessed 5/10/2021) have

identified variants in some, but not all genes likely to be included in NGS tests. Although useful, none of these

genomic DNA samples, individually or as a group, are sufficient to represent the wide range of variants needed

for a thorough and comprehensive validation of an NGS assay.

As NGS tests have grown to include hundreds to thousands of genes, it has become technically and economically impractical to rely exclusively on DNA samples for assay development and validation studies to assess assay performance. Procuring sufficient reference materials containing specific variants has always been challenging and can be virtually impossible for large gene panels, particularly those that span multiple disorders. In addition, the commoditization of genomic testing and the availability of “off-the-shelf” gene panels have facilitated implementation of genomic tests. Well established laboratories with longstanding clinical expertise often have archived DNA which can be used as reference materials for test development. In contrast, laboratories that do not already have in-depth expertise in the genomic profile of the disorders included in the panels are faced with a paucity of organized resources and guidance as to which clinically important variants require specific attention during test development. The FDA and professional organizations including the College of American Pathologists have begun to acknowledge these challenges and have responded with guidance that permits use of *in silico* reference materials to supplement clinical test validation and operation (Food and Drug Administration <https://www.fda.gov/media/99208/download>, accessed 3/23/2021; College of American Pathologists, Molecular Pathology 2020 checklist <https://www.cap.org/> registration required, accessed 3/23/2021).

In 2019, the Clinical Laboratory Improvement Advisory Committee (CLIAAC) issued a recommendation to the Department of Health and Human Services that the GeT-RM program should develop electronic reference materials for NGS testing (https://www.cdc.gov/cliac/docs/summary/cliac0419_summary.pdf accessed 5/10/2021). As a first step towards this goal, GeT-RM has partnered with the Clinical Genome Resource (ClinGen, <https://www.clinicalgenome.org/> accessed 2/27/2021) to develop lists of expert curated, clinically important variants. This publication describes these variant lists, which can be used to inform test validation studies and will serve as a foundation for creating multi-variant electronic reference materials by *in silico* mutagenesis of laboratory generated BAM or FASTQ files.⁹⁻¹¹

Methods

Variant nomination process

Members of 36 expert panels, including 35 of ClinGen's Variant Curation Expert Panels (VCEPs), and experts from the CFTR2 Project were contacted in March 2020 and asked to nominate clinically important variants in the genes covered by the expert panels. FDA has recognized ClinGen's curation process and its resulting variant classifications as a regulatory-grade variant database (ClinGen <https://clinicalgenome.org/docs/fda-recognizes-clingen-assertions-in-clinvar-frequently-asked-questions/> accessed 5/10/2021; Food and Drug Administration <https://www.fda.gov/news-events/press-announcements/fda-takes-new-action-advance-development-reliable-and-beneficial-genetic-tests-can-improve-patient> accessed 5/10/2021). These VCEP curated, FDA recognized variants are available via NCBI's ClinVar database and ClinGen's Evidence Repository (<https://erepo.clinicalgenome.org> accessed 5/10/2021).

Each expert panel was asked to nominate a minimum of 10 variants per disease area, including pathogenic variants that are the largest contributors to a disease as well as variants that may represent potential analytic challenges to laboratories. Panels submitted their variant nominations on a standardized template from April-June 2020. For each variant, the panels noted if the basis for inclusion was: a) Major contributor to disease, b) Analytic detection difficult, c) Filtration impact (may be inadvertently filtered out due to high allele frequency), or d) Other (with explanation provided in a comment box). The panels were instructed that any reason for difficult detection was appropriate including: variant type, homology issues or a high allele frequency for a lower penetrant variant that might make the variant excluded by standard allele frequency filters. The ClinGen Allele Registry was used to standardize nomenclature for all nominated variants and ClinVar Variation IDs and associated disorders were added where available. A full list of the expert panels that contributed variants can be found in Supplemental Table 1 and the full list of nominated variants can be found in Supplemental Table 2.

Not all of the ClinGen VCEPs that participated in this project have completed all four steps of the VCEP development process required for final approval by ClinGen¹² (ClinGen <https://clinicalgenome.org/docs/guidelines-for-applying-for-variant-or-gene-curation-expert-panel-status/> accessed 3/23/2021). Of the variants submitted by the panels, 38% are from expert panels with final ClinGen approval to submit to ClinVar as ‘reviewed by expert panel’, whereas 62% are from ClinGen VCEPs that were still developing disease specifications for variant classification and were not yet fully ClinGen-approved at the time of submission of variants to the project. VCEP status at the time of manuscript submission is shown in column B of Supplemental table 2. Current status can be found on the ClinGen website (<https://clinicalgenome.org/working-groups/clinical-domain/> accessed 3/23/2021).

Limitations of variant selection process

Several limitations of the variant selection process should be noted. There were no explicit requirements given to the expert panels in terms of the definitions of categories a, b, and c and therefore each may have used slightly different definitions to select variants to nominate for this project. In addition, some expert panels may have used laboratory data that is not in the public domain to identify nominated variants and this information was not requested during the submission process. Furthermore, some expert panels represent genes and diseases that are very rare and therefore variants may not, in general, be highly prevalent. These are not considered serious limitations as these are “first-generation” variant lists, which provide an entirely new resource. It is expected that this effort will continue in years to come to broaden and deepen this resource.

Results

Nominations of clinically important pathogenic or difficult to detect variants were received from 24 expert panels out of 36 contacted (Supplemental Table 1). Overall, 546 unique variants in 84 genes were nominated (Supplemental Table 2) including 22 of the 59 genes recommended by ACMG for reporting of incidental or

secondary findings, which are included as part of virtually all proactive genomic health tests.¹² The nominated variants are causative for a wide range of diseases many of which are commonly tested by NGS including heritable cancers, inborn errors of metabolism, cardiomyopathy, diabetes, and immune disorders (Table 1). A number of different variant types were nominated, including 346 SNVs, 104 deletions, 37 CNVs, 25 duplications, 18 deletion-insertions, 5 inversions, 4 insertions, 2 complex rearrangements, 2 fusions, and 3 variants in regions defined as “difficult region to cover and map variants”. The variants were nominated for a variety of reasons: 355 are major contributors to disease, 111 are analytically difficult to detect, 28 may have filtration impacts (be inadvertently filtered out due to high allele frequency), 6 had multiple reasons for inclusion, and 46 were listed as “other” or no explanation was provided (Supplemental Table 2).

Discussion

Clinical laboratories in the United States are required by regulation and guided by professional or best practice standards to use characterized reference materials for test development, validation and verification studies, quality control and proficiency testing¹³⁻¹⁶ (American College of Medical Genetics <https://www.acmg.net/PDFLibrary/Standards-Guidelines-Clinical-Molecular-Genetics.pdf>, accessed 4/9/2020, Washington State Legislature, <http://app.leg.wa.gov/WAC/default.aspx?cite=246-338-090>, accessed 4/9/2020, College of American Pathologists <https://www.cap.org/>, accessed 4/9/2020 (registration required), New York State Clinical Laboratory Evaluation Program, <http://www.wadsworth.org/clep>, accessed 4/9/2020).

Certain aspects of test development and validation, such as DNA extraction, library preparation, and sequence generation will always require the use of genomic DNA from cell lines or patient samples. However, given the scope of many NGS tests, it is no longer feasible to rely solely upon genomic DNA samples containing only one or a few variants of interest to validate an assay that tests an entire exome or genome or many genes within a large NGS panel, and novel types of reference materials are needed to enable assessment of a test’s analytical validity and establish adequate clinical validity.

212

213 The Association for Molecular Pathology and the College of American Pathologists allow the use of *in silico*
 214 reference materials to supplement genomic DNA for the validation of bioinformatic pipelines (College of
 215 American Pathologists, Molecular Pathology 2020 checklist <https://www.cap.org/> registration required,
 216 accessed 3/23/2021).^{4, 17-19} Specialized software^{9, 10, 20} has been developed to edit sequence variants into BAM
 217 or FASTQ files generated by the assay being validated to create customized reference materials. The software is
 218 publicly available, and several companies offer this service to laboratories. The GeT-RM program is planning to
 219 use these curated variants and file editing software to pilot development and use of *in silico* reference materials
 220 in clinical laboratories.

221

222 The number of variants that can be added is potentially unlimited, but care must be taken to avoid adding too
 223 many variants in *cis* to the same sequence reads because it may affect alignment to the reference sequence. The
 224 types of variants that can be introduced remains limited to SNVs and smaller insertions and deletions at
 225 different allele fractions, although the ability to introduce CNVs is currently being developed. This approach has
 226 been used successfully by the College of American Pathologists for its NGS proficiency testing challenges.^{9, 10}

227

228 The variant list developed by the effort presented here is available on the GeT-RM and ClinGen websites and can
 229 serve as a knowledge resource to help laboratories identify important pathogenic and difficult to detect variants
 230 in genes that are included in their assays, as well as a foundation for generating customized *in silico* reference
 231 materials. GeT-RM and ClinGen will continue to collaborate to add to the current variant list and invite input
 232 from the genetics community about this list and the processes used to generate it.

233

234

235

236

237 **Table 1.** Summary of the numbers of variants per gene nominated

Gene	HGNC Gene ID	# Variants nominated	Disorder
ACADVL	HGNC:92	10	Very long-chain acyl-CoA dehydrogenase deficiency
ACVRL1	HGNC:175	3	Hereditary hemorrhagic telangiectasia, type 2
APC	HGNC:583	4	Familial adenomatous polyposis
ATM	HGNC:795	6	Hereditary breast carcinoma (AD) Ataxia telangiectasia (AR)
BARD1	HGNC:952	5	Hereditary breast carcinoma
BRAF	HGNC:1097	1	Cardiofaciocutaneous syndrome
BRCA1	HGNC:1100	26	Breast-ovarian cancer, familial, susceptibility to, 1 (AD)
BRCA2	HGNC:1101	22	Breast-ovarian cancer, familial, susceptibility to, 2 (AD)
BRIP1	HGNC:20473	5	Familial ovarian cancer (AD) Fanconi anemia complementation group J (AR)
BTK	HGNC:1133	10	X-linked agammaglobulinemia (XLA)
CARD11	HGNC:16393	5	CARD11 defects
CDH1	HGNC:1748	10	Hereditary diffuse gastric adenocarcinoma

CFH	HGNC:4883	5	Atypical hemolytic uremic syndrome (aHUS)/Thrombotic microangiopathy (TMA)
CFTR	HGNC:1884	14	Cystic fibrosis
CHEK2	HGNC:16627	5	Hereditary breast carcinoma
COL6A1	HGNC:2211	1	Congenital muscular dystrophy
CYP1B1	HGNC:2597	3	Congenital glaucoma
DCLRE1C	HGNC:17642	8	Severe combined immunodeficiency due to DCLRE1C deficiency
DES	HGNC:2770	17	Arrhythmogenic right ventricular cardiomyopathy (arrhythmogenic cardiomyopathy)
DICER1	HGNC:17098	7	Pleuropulmonary blastoma
DNM2	HGNC:2974	3	Centronuclear myopathy
DSC2	HGNC:3036	5	Arrhythmogenic right ventricular cardiomyopathy (arrhythmogenic cardiomyopathy)
DSG2	HGNC:3049	7	Arrhythmogenic right ventricular cardiomyopathy (arrhythmogenic cardiomyopathy)
DSP	HGNC:3052	10	Arrhythmogenic right ventricular cardiomyopathy (arrhythmogenic cardiomyopathy)

ENG	HGNC:3349	4	Hereditary hemorrhagic telangiectasia
FBN1	HGNC:3603	10	Marfan syndrome, familial thoracic aortic aneurysm and aortic dissection
GAA	HGNC:4065	8	Glycogen storage disease type II
GATA2	HGNC:4171	15	GATA2 deficiency with susceptibility to MDS/AML; GATA2 haploinsufficiency
GCK	HGNC:4195	11	Monogenic diabetes
HBA1*	HGNC:4823	4	Alpha thalassemia, Hemoglobin H disease, Hemoglobin Bart's hydrops fetalis
HBA2*	HGNC:4824	7	Alpha thalassemia, Hemoglobin H disease, Hemoglobin Bart's hydrops fetalis
HBB*	HGNC:4827	10	Sickle cell anemia, sickle cell disease associated with another hemoglobin anomaly, Beta thalassemia, Sickle cell-beta-thalassemia disease syndrome, Sickle cell-hemoglobin C disease syndrome, Hemoglobin C-beta-thalassemia syndrome, Hemoglobin C disease, Sickle cell-hemoglobin D disease syndrome, Hemoglobin D disease, Sickle cell-hemoglobin E disease syndrome, Hemoglobin E-beta-thalassemia syndrome, Hemoglobin E disease, Hemoglobin Lepore-beta-thalassemia syndrome

HBD*	HGNC:4829	1	Hemoglobin Lepore-beta-thalassemia syndrome, sickle cell-beta-thalassemia disease syndrome
HBQ1	HGNC:4833	1	Alpha thalassemia, Hemoglobin H disease, Hemoglobin Bart's hydrops fetalis
HNF1A	HGNC:11621	2	Monogenic diabetes
HNF1B	HGNC:11630	1	Monogenic diabetes
HNF4A	HGNC:5025	3	Monogenic diabetes
HRAS	HGNC:5173	1	Costello syndrome
IKBKG	HGNC:5961	6	NEMO (NFkB essential modulator) deficiency
IL2RG	HGNC:6010	10	SCID (severe combined immunodeficiency)
INS	HGNC:6081	1	Monogenic diabetes
JAK3	HGNC:6193	5	SCID (severe combined immunodeficiency)
LDLR	HGNC:6547	10	Familial hypercholesterolemia
LRBA	HGNC:1742	5	LRBA deficiency
LYST	HGNC:1968	5	Chediak-Higashi syndrome (CHS)
MAP2K1	HGNC:6840	1	Cardiofaciocutaneous syndrome
MLH1	HGNC:7127	19	Colorectal cancer, hereditary nonpolyposis, type 2

			Constitutional mismatch repair deficiency syndrome
MSH2	HGNC:7325	16	Lynch syndrome
MSH6	HGNC:7329	7	Lynch syndrome
MUTYH	HGNC:7527	2	MUTYH-related attenuated familial adenomatous polyposis (AR/AD)
MYBPC3	HGNC:7551	16	Hypertrophic cardiomyopathy
MYH7	HGNC:7577	6	Hypertrophic cardiomyopathy
MYOC	HGNC:7610	4	Open angle glaucoma
NCF1	HGNC:7660	6	Chronic Granulomatous Disease (CGD)
NEB	HGNC:7720	2	Nemaline myopathy
NTHL1	HGNC:8028	1	Familial adenomatous polyposis
PAH	HGNC:8582	17	Phenylketonuria
PALB2	HGNC:26144	5	Hereditary breast carcinoma (AD), Fanconi anemia complementation group N (AR)
PKP2	HGNC:9024	22	Arrhythmogenic right ventricular cardiomyopathy (arrhythmogenic cardiomyopathy)
PLN	HGNC:9080	4	Arrhythmogenic right ventricular cardiomyopathy (arrhythmogenic cardiomyopathy)
POLD1	HGNC:9175	1	Polymerase proofreading-related adenomatous polyposis
POLE	HGNC:9177	1	Polymerase proofreading-related adenomatous polyposis

PTEN	HGNC:9588	5	PTEN hamartoma tumor syndrome
PTPN11	HGNC:9644	4	Noonan syndrome, Noonan syndrome with multiple lentigines
RAD51C	HGNC:9820	5	Familial ovarian cancer (AD)
RAD51D	HGNC:9823	5	Familial ovarian cancer (AD)
RAF1	HGNC:9829	1	Noonan syndrome
RAG1	HGNC:9831	7	SCID (severe combined immunodeficiency)
RUNX1	HGNC:10471	10	Familial platelet disorder with associated myeloid malignancy
RYR1**	HGNC:10483	17	Susceptibility to malignant hyperthermia (AD) Central core myopathy (AR/AD)
SELENON	HGNC:15999	4	Rigid spine myopathy
SHOC2	HGNC:15454	1	Noonan syndrome-like disorder with loose anagen hair
SMAD4	HGNC:6770	3	Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome
SOS1	HGNC:11187	1	Noonan syndrome
TMEM43	HGNC:28472	1	Arrhythmogenic right ventricular cardiomyopathy (arrhythmogenic cardiomyopathy)

TNNI3	HGNC:11947	1	Hypertrophic cardiomyopathy
TNNT2	HGNC:11949	2	Hypertrophic cardiomyopathy, dilated cardiomyopathy
TP53	HGNC:11998	10	Li-Fraumeni syndrome
TPM2	HGNC:12011	1	Nemaline myopathy
TPM3	HGNC:12012	3	Nemaline myopathy
TTN	HGNC:12403	7	Distal titinopathy, tibial muscular dystrophy, hereditary myopathy with early respiratory failure
VHL	HGNC:12687	7	Von Hippel-Lindau disease
WAS	HGNC:12731	13	Wiskott- Aldrich syndrome (WAS)
WFS1	HGNC:12762	1	Monogenic diabetes
* Some variants in these genes are multi-gene deletions or fusions.			
**One variant in RYR1 was submitted by both the Congenital Myopathies and Malignant Hyperthermia Susceptibility VCEPs.			

238

239 Suppl Table 1. List of participating expert panels and names of participants

240 Suppl Table 2. List of variants nominated

241

242 References

- 243 1. Mandelker D, Schmidt RJ, Ankala A, McDonald Gibson K, Bowser M, Sharma H, Duffy E, Hegde M,
244 Santani A, Lebo M, Funke B: Navigating highly homologous genes in a molecular diagnostic setting: a
245 resource for clinical next-generation sequencing. Genetics in medicine : official journal of the American
246 College of Medical Genetics 2016, 18:1282-1289.

- 247 2. Bean LJH, Funke B, Carlston CM, Gannon JL, Kantarci S, Krock BL, Zhang S, Bayrak-Toydemir P,
248 Committee ALQA: Diagnostic gene sequencing panels: from design to report-a technical standard of the
249 American College of Medical Genetics and Genomics (ACMG). *Genetics in medicine : official journal of*
250 *the American College of Medical Genetics* 2020, 22:453-461.
- 251 3. Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, Ledbetter DH, Maglott DR, Martin
252 CL, Nussbaum RL, Plon SE, Ramos EM, Sherry ST, Watson MS, ClinGen: ClinGen--the Clinical Genome
253 Resource. *The New England journal of medicine* 2015, 372:2235-2242.
- 254 4. Clinical and Laboratory Standards Institute: MM17 Validation and Verification of Multiplex Nucleic Acid
255 Assays, 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2018.
- 256 5. Zook JM, Catoe D, McDaniel J, Vang L, Spies N, Sidow A, Weng Z, Liu Y, Mason CE, Alexander N, Henaff E,
257 McIntyre ABR, Chandramohan D, Chen F, Jaeger E, Moshrefi A, Pham K, Stedman W, Liang T, Saghbini M,
258 Dzakula Z, Hastie A, Cao H, Deikus G, Schadt E, Sebra R, Bashir A, Truty RM, Chang CC, Gulbahce N, Zhao
259 K, Ghosh S, Hyland F, Fu Y, Chaisson M, Xiao C, Trow J, Sherry ST, Zaranek AW, Ball M, Bobe J, Estep P,
260 Church GM, Marks P, Kyriazopoulou-Panagiotopoulou S, Zheng GXY, Schnall-Levin M, Ordonez HS,
261 Mudivarti PA, Giorda K, Sheng Y, Rypdal KB, Salit M: Extensive sequencing of seven human genomes to
262 characterize benchmark reference materials. *Scientific Data* 2016, 3:160025.
- 263 6. Wang Y-C, Olson ND, Deikus G, Shah H, Wenger AM, Trow J, Xiao C, Sherry S, Salit ML, Zook JM, Smith M,
264 Sebra R: High-coverage, long-read sequencing of Han Chinese trio reference samples. *Scientific Data*
265 2019, 6:91.
- 266 7. Zook JM, McDaniel J, Olson ND, Wagner J, Parikh H, Heaton H, Irvine SA, Trigg L, Truty R, McLean CY, De
267 La Vega FM, Xiao C, Sherry S, Salit M: An open resource for accurately benchmarking small variant and
268 reference calls. *Nature biotechnology* 2019, 37:561-566.
- 269 8. Eberle MA, Fritzilas E, Krusche P, Kallberg M, Moore BL, Bekritsky MA, Iqbal Z, Chuang HY, Humphray SJ,
270 Halpern AL, Kruglyak S, Margulies EH, McVean G, Bentley DR: A reference data set of 5.4 million phased
271 human variants validated by genetic inheritance from sequencing a three-generation 17-member
272 pedigree. *Genome Res* 2017, 27:157-164.
- 273 9. Duncavage EJ, Abel HJ, Pfeifer JD: In Silico Proficiency Testing for Clinical Next-Generation Sequencing.
274 *The Journal of molecular diagnostics : JMD* 2017, 19:35-42.
- 275 10. Duncavage EJ, Abel HJ, Merker JD, Bodner JB, Zhao Q, Voelkerding KV, Pfeifer JD: A Model Study of In
276 Silico Proficiency Testing for Clinical Next-Generation Sequencing. *Archives of pathology & laboratory*
277 *medicine* 2016, 140:1085-1091.
- 278 11. Li Z, Fang S, Zhang R, Yu L, Zhang J, Bu D, Sun L, Zhao Y, Li J: VarBen: Generating in Silico Reference Data
279 Sets for Clinical Next-Generation Sequencing Bioinformatics Pipeline Evaluation. *The Journal of*
280 *molecular diagnostics : JMD* 2021, 23:285-299.
- 281 12. Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, Herman GE, Hufnagel SB, Klein TE, Korf BR,
282 McKelvey KD, Ormond KE, Richards CS, Vlangos CN, Watson M, Martin CL, Miller DT, on behalf of the
283 ASFMWG: Recommendations for reporting of secondary findings in clinical exome and genome
284 sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical
285 Genetics and Genomics. *Genetics in Medicine* 2017, 19:249-255.
- 286 13. Chen B, Gagnon M, Shahangian S, Anderson NL, Howerton DA, Boone JD, Centers for Disease C,
287 Prevention: Good laboratory practices for molecular genetic testing for heritable diseases and
288 conditions. *MMWR Recommendations and reports : Morbidity and mortality weekly report*
289 *Recommendations and reports / Centers for Disease Control* 2009, 58:1-37; quiz CE-31-34.
- 290 14. Association for Molecular Pathology statement. Recommendations for in-house development and
291 operation of molecular diagnostic tests. *Am J Clin Pathol* 1999, 111:449-463.
- 292 15. International Organization for Standardization: ISO 15189 Medical Laboratories: Requirements for
293 Quality and Competence. Geneva. International Organization for Standardization 2012.
- 294 16. Electronic Code of Federal Regulations: The Clinical Laboratory Improvement Amendments (CLIA). Title
295 42 Chapter IV, Subchapter G, Part 493.

296 17. Aziz N, Zhao Q, Bry L, Driscoll DK, Funke B, Gibson JS, Grody WW, Hegde MR, Hoeltge GA, Leonard DG,
297 Merker JD, Nagarajan R, Palicki LA, Robetorye RS, Schrijver I, Weck KE, Voelkerding KV: College of
298 American Pathologists' laboratory standards for next-generation sequencing clinical tests. Archives of
299 pathology & laboratory medicine 2015, 139:481-493.

300 18. Roy S, Coldren C, Karunamurthy A, Kip NS, Klee EW, Lincoln SE, Leon A, Pullambhatla M, Temple-Smolkin
301 RL, Voelkerding KV, Wang C, Carter AB: Standards and Guidelines for Validating Next-Generation
302 Sequencing Bioinformatics Pipelines: A Joint Recommendation of the Association for Molecular
303 Pathology and the College of American Pathologists. The Journal of molecular diagnostics : JMD 2018,
304 20:4-27.

305 19. Santani A, Simen BB, Briggs M, Lebo M, Merker JD, Nikiforova M, Vasalos P, Voelkerding K, Pfeifer J,
306 Funke B: Designing and Implementing NGS Tests for Inherited Disorders: A Practical Framework with
307 Step-by-Step Guidance for Clinical Laboratories. The Journal of molecular diagnostics : JMD 2019,
308 21:369-374.

309 20. Patil SA, Mujacic I, Ritterhouse LL, Segal JP, Kadri S: insiM: in silico Mutator Software for Bioinformatics
310 Pipeline Validation of Clinical Next-Generation Sequencing Assays. The Journal of molecular diagnostics :
311 JMD 2019, 21:19-26.

312